Drug of choice for supraventricular tachycardia
Drug of choice for supraventricular tachycardia Supraventricular tachycardia (SVT) is a common cardiac arrhythmia characterized by an abnormally fast heartbeat originating above the ventricles. It often presents with sudden episodes of rapid palpitations, dizziness, shortness of breath, or chest discomfort. While many individuals may experience occasional episodes that resolve spontaneously, others require medical intervention to restore normal heart rhythm and prevent complications.
The management of SVT hinges on several factors, including the severity and duration of episodes, the patient’s overall health, and the presence of underlying heart conditions. In acute settings, initial treatment strategies often focus on vagal maneuvers, which are simple techniques intended to stimulate the vagus nerve and slow conduction through the atrioventricular (AV) node. These maneuvers include the Valsalva maneuver, carotid sinus massage, or immersion of the face in cold water. When vagal techniques fail to terminate the episode, pharmacologic therapy becomes necessary. Drug of choice for supraventricular tachycardia
The drug of choice for acute termination of SVT is typically adenosine. Adenosine acts rapidly to transiently block conduction through the AV node, which is the common pathway for many SVT mechanisms, especially reentrant types like AV nodal reentrant tachycardia (AVNRT). Its rapid onset and brief duration of action—often less than a minute—make it highly effective and safe for emergency use. When administered intravenously, usually as a rapid bolus, adenosine can quickly restore normal sinus rhythm in most cases. Its side effects are generally short-lived and include sensations like flushing, chest discomfort, or brief asystole, which are usually well tolerated in a monitored setting. Drug of choice for supraventricular tachycardia
Other antiarrhythmic agents may be considered if adenosine is contraindicated or ineffective. For example, calcium channel blockers such as verapamil or diltiazem are effective in slowing AV nodal conduction and converting SVT to sinus rhythm. These drugs are particularly useful in patients with frequent episodes or in those who cannot tolerate adenosine. However, they must be used cautiously, especially in patients with hypotension or congestive heart failure, due to their negative inotropic effects.
Beta-blockers like metoprolol also have a role in both acute and chronic management of SVT. They work by decreasing sympathetic stimulation and reducing the frequency of episodes. In some cases, antiarrhythmic drugs like procainamide or flecainide may be employed, especially when other options are unsuitable or ineffective. Drug of choice for supraventricular tachycardia
Drug of choice for supraventricular tachycardia While pharmacologic therapy is crucial for acute management, long-term control may involve catheter ablation, which targets the abnormal conduction pathways responsible for SVT. This procedure offers a potential cure and is considered when episodes are frequent or significantly impair quality of life.
In summary, adenosine remains the primary drug of choice for the acute termination of SVT due to its rapid action and safety profile. Its use, complemented by other medications and invasive procedures when necessary, forms a comprehensive approach to managing this common arrhythmia. Drug of choice for supraventricular tachycardia
